返回排名列表

BGM Group Ltd. (BGM)

NEGATIVE
HealthcareDrug Manufacturers - Specialty & GenericChina

基本面

~22

价格

$0.25

市值

$100M

第一部分 · 这家公司值多少

概览

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

可用财务数据有限(37% 的指标)。评分可能无法准确反映该公司的基本面。

资产负债表与流动性

营收

$74M

净利润

$-39M

自由现金流

-

股东权益合计

$742M

负债合计

-

流动比率

1.24

利息覆盖率

-

债务/EBITDA

-

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

Pre-revenue被高估
For a company classified as Pre-revenue, the appropriate models don't have enough data. The value below comes from the generic methods, which are less reliable for this kind of business: read it as an order of magnitude, and look at the range rather than the single number.

公允价值

$0.10

当前价格

$0.25

安全边际

-154.5%

公允价值区间

$0.08 - $0.13

估算方法

Analyst price target:Not enough data to compute it
Discounted cash flow (DCF):$0.10
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):Not enough data to compute it
Justified P/B:Not applicable to this type of company
Dividend discount (Gordon):Not applicable to this type of company
P/FFO, funds from operations:Not applicable to this type of company
Mid-cycle earnings:Not applicable to this type of company
Revenue multiple:Not enough data to compute it

估值指标

市盈率(P/E)

-

ROE

-7.0%

市净率(P/B)

0.15

P/FCF

31.32

毛利率

16.6%

ROIC

-1.8%

盈利能力雷达图

Value Creation (Economic Moat)

ROIC

-1.8%

WACC

14.5%

ROIC − WACC

-16.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

基本面分析标准

通过(2)

  • P/B Ratio 0.15
  • Current Ratio

未通过(8)

  • Price CAGR -54.38%
  • ROIC -1.8%
  • Gross Margin 16.6%
  • P/FCF 31.32
  • DCF valuation (Overvalued)
  • ROE -7.0%
  • Revenue Growth 5Y -5.4%
  • Piotroski F-Score 0/9

不可用(17)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Debt/Equity ratio
  • Operating Margin NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • Analyst Consensus (Finnhub)
  • Earnings Surprise (Finnhub)
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)
  • Share Dilution (need 2+ years)
  • Net Margin Trend (invalid data)

Piotroski F-评分

0/9

存在严重财务隐患

score
criteria

盈利质量

-

低质量:需深入审查会计处理

股权稀释

-

正在回购股份,对股东友好

公司治理

管理团队

姓名职位年龄
Ms. Huandi ZhaoCo-Chief Executive Officer & Director40
Ms. Li HongCo-Chief Executive Officer-
Ms. Yaxuan ZhaiChief Financial Officer30

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

Latest News

Recent headlines for BGM, sourced from Markets Gazette.

No recent news for BGM.